查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1831828

2025-2033年抗体药物偶联物市场报告（按成分、目标、应用、最终用户和地区）

Antibody Drug Conjugates Market Report by Component, Target, Application, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球抗体药物偶联物市场规模达 94 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 502 亿美元，2025-2033 年期间的成长率 (CAGR) 为 19.45%。

抗体药物偶联物 (ADC) 是一种高效生物药物，由靶向肿瘤的抗体透过化学方式与细胞毒性效应分子连接而成。它们透过可生物降解的连接体将细胞毒性抗癌药物与单株抗体 (mAb) 连接，从而将细胞毒性抗癌药物递送至受影响的细胞，并允许健康组织和患病组织之间进行灵敏的分叉。与标准化疗生物活性化合物相比，ADC 有助于增强 mAb 的细胞杀伤潜力、增强药物耐受性并降低系统性暴露。目前，它们透过静脉注射进入血液，以避免胃酸和蛋白质水解酶降解 mAb。

抗体药物偶联物市场趋势：

由于久坐不动的生活方式以及吸烟和饮酒习惯的不断增加，全球癌症的发生率正在上升。这与对经济高效且有效的癌症治疗方案日益增长的需求相结合，是推动市场成长的关键因素之一。此外，现有的连接体通常会非特异性地释放有效载荷，并导致脱靶毒性，这严重影响了ADC的开发。因此，领先的企业正在持续投资其研发项目，以优化现有的化学触发剂，并开发新型化学触发剂，从而产生高选择性的连接体。他们还开发了新型的连接体-抗体连接体，以生产稳定均质的ADC，以及额外的连接体-有效载荷连接体，以扩展有效载荷。此外，他们还致力于改善药物的吸收、分布、代谢和排泄，这为市场前景创造了良好的前景。其他主要因素，包括显着改善医疗保健基础设施、提高对癌症治疗方法的认识以及可裂解连接技术的引入，预计将推动市场成长。

本报告回答的关键问题：

  • 全球抗体药物偶联物市场迄今表现如何，未来几年将如何表现？
  • COVID-19 对全球抗体药物偶联物市场有何影响？
  • 主要的区域市场有哪些？
  • 根据组成部分，市场是如何分類的？
  • 根据目标，市场区隔如何？
  • 根据应用，市场是如何分類的？
  • 根据最终用户，市场是如何分類的？
  • 该产业的价值链分为哪些阶段？
  • 该行业的主要驱动因素和挑战是什么？
  • 全球抗体药物偶联物市场的结构是怎么样的？主要参与者是谁？
  • 产业竞争程度如何？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球抗体药物偶联物市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：按组成部分

  • 单株抗体
  • 连结器
  • 细胞毒剂
  • 其他的

第七章：市场区隔：依目标

  • 抗体-蛋白质毒素结合物
  • 抗体螯合放射性核种结合物
  • 抗体-小分子药物偶联物
  • 抗体-酵素结合物

第 8 章：市场区隔：按应用

  • 淋巴瘤
  • 卵巢癌
  • 肺癌
  • 乳癌
  • 脑肿瘤
  • 其他的

第九章：市场区隔：依最终用户

  • 医院
  • 专门的癌症中心
  • 学术研究机构
  • 生技公司
  • 其他的

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 11 章：SWOT 分析

第 12 章：价值链分析

第 13 章：波特五力分析

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • ADC Therapeutics SA
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Celldex Therapeutics Inc.
    • F. Hoffmann-La Roche AG
    • Gilead Sciences Inc.
    • GlaxoSmithKline Plc
    • ImmunoGen Inc
    • Pfizer Inc.
    • Sanofi SA
    • Seagen Inc.
    • Sorrento Therapeutics Inc.
    • Takeda Pharmaceutical Company Ltd.
Product Code: SR112025A4604

The global antibody drug conjugates market size reached USD 9.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 50.2 Billion by 2033, exhibiting a growth rate (CAGR) of 19.45% during 2025-2033.

Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb.

Antibody Drug Conjugates Market Trends:

Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth.

Key Market Segmentation:

Breakup by Component:

  • Monoclonal Antibodies
  • Linker
  • Cytotoxic Agent
  • Others

Breakup by Target:

  • Antibody-Protein Toxin Conjugates
  • Antibody-Chelated Radionuclide Conjugates
  • Antibody-Small-Molecule Drug Conjugates
  • Antibody-Enzyme Conjugates

Breakup by Application:

  • Lymphoma
  • Ovarian Cancer
  • Lung Cancer
  • Breast Cancer
  • Brain Tumor
  • Others

Breakup by End User:

  • Hospitals
  • Specialized Cancer Centers
  • Academic Research Institutes
  • Biotechnology Companies
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.

Key Questions Answered in This Report:

  • How has the global antibody drug conjugates market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global antibody drug conjugates market?
  • What are the key regional markets?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the target?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global antibody drug conjugates market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antibody Drug Conjugates Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Linker
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cytotoxic Agent
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Target

  • 7.1 Antibody-Protein Toxin Conjugates
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antibody-Chelated Radionuclide Conjugates
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Antibody-Small-Molecule Drug Conjugates
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antibody-Enzyme Conjugates
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Lymphoma
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ovarian Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Lung Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Breast Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Brain Tumor
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Specialized Cancer Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Academic Research Institutes
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Biotechnology Companies
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 ADC Therapeutics SA
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Astellas Pharma Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Celldex Therapeutics Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Gilead Sciences Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 GlaxoSmithKline Plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 ImmunoGen Inc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Seagen Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sorrento Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
    • 15.3.13 Takeda Pharmaceutical Company Ltd.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Antibody Drug Conjugates Market: Major Drivers and Challenges
  • Figure 2: Global: Antibody Drug Conjugates Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Antibody Drug Conjugates Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Antibody Drug Conjugates Market: Breakup by Component (in %), 2024
  • Figure 5: Global: Antibody Drug Conjugates Market: Breakup by Target (in %), 2024
  • Figure 6: Global: Antibody Drug Conjugates Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Antibody Drug Conjugates Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Antibody Drug Conjugates Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Antibody Drug Conjugates (Linker) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Antibody Drug Conjugates (Linker) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Antibody Drug Conjugates (Other Components) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Antibody Drug Conjugates (Other Components) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Antibody Drug Conjugates (Lymphoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Antibody Drug Conjugates (Lymphoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Antibody Drug Conjugates (Ovarian Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Antibody Drug Conjugates (Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Antibody Drug Conjugates (Lung Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Antibody Drug Conjugates (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Antibody Drug Conjugates (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Antibody Drug Conjugates (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Antibody Drug Conjugates (Brain Tumor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Antibody Drug Conjugates (Brain Tumor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Antibody Drug Conjugates (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Antibody Drug Conjugates (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Antibody Drug Conjugates (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Antibody Drug Conjugates (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Antibody Drug Conjugates (Academic Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Antibody Drug Conjugates (Academic Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Antibody Drug Conjugates (Biotechnology Companies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Antibody Drug Conjugates (Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Global: Antibody Drug Conjugates (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Global: Antibody Drug Conjugates (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: North America: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: North America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: United States: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: United States: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Canada: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Canada: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Asia-Pacific: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Asia-Pacific: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: China: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: China: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Japan: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Japan: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: India: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: India: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: South Korea: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: South Korea: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Australia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Australia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Indonesia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Indonesia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Europe: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Europe: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Germany: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Germany: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: France: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: France: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: United Kingdom: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: United Kingdom: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Italy: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Italy: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Spain: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Spain: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Russia: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Russia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Latin America: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Latin America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Brazil: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Brazil: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Mexico: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Mexico: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Others: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Middle East and Africa: Antibody Drug Conjugates Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 94: Middle East and Africa: Antibody Drug Conjugates Market: Breakup by Country (in %), 2024
  • Figure 95: Middle East and Africa: Antibody Drug Conjugates Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 96: Global: Antibody Drug Conjugates Industry: SWOT Analysis
  • Figure 97: Global: Antibody Drug Conjugates Industry: Value Chain Analysis
  • Figure 98: Global: Antibody Drug Conjugates Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antibody Drug Conjugates Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Antibody Drug Conjugates Market Forecast: Breakup by Component (in Million USD), 2025-2033
  • Table 3: Global: Antibody Drug Conjugates Market Forecast: Breakup by Target (in Million USD), 2025-2033
  • Table 4: Global: Antibody Drug Conjugates Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Antibody Drug Conjugates Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Antibody Drug Conjugates Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Antibody Drug Conjugates Market: Competitive Structure
  • Table 8: Global: Antibody Drug Conjugates Market: Key Players